Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 11:5:430.
doi: 10.1186/s40064-016-2058-z. eCollection 2016.

Recurrence and death after Clostridium difficile infection: gender-dependant influence of proton pump inhibitor therapy

Ophélie Dos Santos-Schaller  1 , Sandrine Boisset  2 , Arnaud Seigneurin  3 , Olivier Epaulard  4
Affiliations

Recurrence and death after Clostridium difficile infection: gender-dependant influence of proton pump inhibitor therapy

Ophélie Dos Santos-Schaller et al. Springerplus. .

Abstract

Goals: To determine whether patients with a pre-existing PPI treatment had a higher risk of poor evolution (recurrence or death) when diagnosed with a toxicogenic Clostridium difficile digestive infection.

Background: Previous studies identified pump proton inhibitor (PPI) prescription as a risk factor for C. difficile infection. The influence of PPI on the outcome of C. difficile infection is controversial.

Study: This was a retrospective monocentric cohort study. All cases of patients in our center with a symptomatic infection by a toxicogenic C. difficile strain during the years 2012 and 2013 were retrospectively analyzed. The primary endpoint was the occurrence of a recurrence or C. difficile infection -related death within 2 months after diagnosis.

Results: 373 patients were included in this study (198 men and 175 women), with a mean age of 70.1 ± 18.6 years (2-100 years). Fourteen (3.7 %) patients died secondarily to C. difficile infection (median survival time 5 days), and 88 (23.6 %) experienced recurrence (after a median delay of 30 days). One hundred and ninety eight (53.1 %) patients were already receiving PPI at the time of the C. difficile infection (including 156 patients with a prescription >1 month). When analyzing separately men and women, male patients were more likely to experience recurrence or death in case of pre-existing PPI prescription [HR = 2.32 (1.26-4.27)]; this was not observed in female patients [HR = 0.62 (0.31-1.22)].

Conclusions: Pre-existing PPI therapy may increase the risk of recurrence or death in male patients with a toxicogenic C. difficile infection. PPI risk-benefit ratio should be carefully assessed.

Keywords: Clostridium difficile; Death; Gender; Proton pump inhibitor; Recurrence.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves of the composite risk of C. difficile infection (CDI) recurrence and CDI-related death in males (a) and females (b), in patients with proton pump inhibitor prescription during more than 1 month before CDI diagnosis (bold line) and other patients (thin line)
See this image and copyright information in PMC

References

    1. Boone JH, Goodykoontz M, Rhodes SJ, Price K, Smith J, Gearhart KN, Carman RJ, Kerkering TM, Wilkins TD, Lyerly DM. Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. Eur J Clin Microbiol Infect Dis. 2012;31(7):1551–1559. doi: 10.1007/s10096-011-1477-6. - DOI - PubMed
    1. Buendgens L, Bruensing J, Matthes M, Duckers H, Luedde T, Trautwein C, Tacke F, Koch A. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care. 2014;29(4):696.e11–696.e15. doi: 10.1016/j.jcrc.2014.03.002. - DOI - PubMed
    1. Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, Delmee M, Fitzpatrick F, Ivanova K, Kuijper E, Macovei IS, Mentula S, Mastrantonio P, von Muller L, Oleastro M, Petinaki E, Pituch H, Noren T, Novakova E, Nyc O, Rupnik M, Schmid D, Wilcox MH. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID) Lancet Infect Dis. 2014;14(12):1208–1219. doi: 10.1016/S1473-3099(14)70991-0. - DOI - PubMed
    1. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310–319. doi: 10.1503/cmaj.092129. - DOI - PMC - PubMed
    1. Fashner J, Gitu AC. Common gastrointestinal symptoms: risks of long-term proton pump inhibitor therapy. FP Essent. 2013;413:29–39. - PubMed

LinkOut - more resources